Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Novel Antigen Improves Detection of Anti-Borrelia Antibodies

By LabMedica International staff writers
Posted on 25 Mar 2013
A recombinant antigen has been developed which greatly increases the specificity of anti-Borrelia antibody detection in the diagnosis of Lyme disease. More...


The dimeric outer surface protein C (OspC antigen) provides over 30% higher specificity than traditionally used monomeric forms, while maintaining a high sensitivity, especially in early stage infections.

Recombinant OspC has, for the first time, has been produced in dimeric form using state-of-the-art molecular biological methods. The dimeric OspC advanced antigen demonstrates the same characteristics as the native dimeric protein. Its exceptionally high specificity minimizes the risk of false-positive results and at the same time, it retains a high sensitivity.

Scientists at EUROIMMUN (Luebeck, Germany) have successfully produced recombinant, covalently bound dimeric OspC using genetic techniques which in contrast to native protein which is difficult to isolate, recombinant OspC advanced can be produced using standardized methods, ensuring a highly consistent antigen quality. The OspC advanced antigen improves the performance of both enzyme-linked immunosorbent assays (ELISA) and immunoblots for Borrelia diagnostics.

The Anti-Borrelia Select ELISA immunoglobulin M (IgM), which contains OspC advanced and other diagnostically relevant antigens in its antigenic substrate, provides exceptionally high sensitivity and specificity in the screening step for early-stage borreliosis. The confirmatory immunoblot Anti-Borrelia EUROLINE-RN-AT-adv (IgM), which includes OspC advanced from four different human pathogenic species, Borrelia afzelii, B. burgdorferi, B. garinii, and B. spielmanii, together with the outer surface protein of B. burgdorferi, known as VlsE, and other highly specific antigens, ensures accurate and reliable results in the confirmation of infections.

Antibodies against OspC are found in up to 90% of persons infected with Borrelia and represent the most important marker for early-stage borreliosis. Over 65,400 cases of Lyme borreliosis occur in Europe each year and over 27,000 cases were reported from the USA in 2012. The Anti-Borrelia Select ELISA and the Anti-Borrelia EUROLINE-RN-AT-adv are fast and easy to perform and can be fully automated, making them ideal for use in routine diagnostics.

Related Links:

EUROIMMUN




Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.